Table 1.
Individual characteristics of patients in our cohort
| Pt | Sex | Age (yrs) | IRLS | RLS meds1 | AD meds2 | EDSS | Walking aid | Brain Lesion3 | AI | ID | AMN | AMN onset (yrs) | RLS onset (yrs) | 6MW (m) | TUG (s) | 25-FW (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||||
| RLS + | ||||||||||||||||
|
| ||||||||||||||||
| 3 | F | 41.6 | 26 (6 w/ med) | + | + | 2 | + | − | − | − | + | 30 | 35 | 333.8 | 9.3 | 7.6 |
| 4 | F | 58.7 | 11 | + | − | 3.5 | + | − | − | − | + | 32 | 56 | 395.3 | 8.7 | 6.3 |
| 5 | F | 57.6 | 25 (20 w/ med) | + | + | 2 | − | − | − | + | + | 37 | 43 | 534.3 | 6.6 | 5.6 |
| 17 | F | 57.7 | 13 | − | + | 1 | − | − | − | − | + | NR | 57 | 603.5 | 6.8 | 4.8 |
| 10 | M | 26.0 | 0 | − | − | 2 | + | + | + | − | + | 23 | 22 | 452.0 | 7.4 | 5.6 |
| 22 | F | 39.7 | 13 | − | + | 1.5 | − | − | − | − | + | 31 | 20 | NR | NR | NR |
| 24 | M | 37.6 | 23 | − | − | 3.5 | + | − | − | + | + | 25 | 30 | 368.8 | 13.7 | 8.6 |
| 25 | M | 39.1 | 0 | − | + | 3 | + | + | + | − | + | 30 | 35 | 358.7 | 8.8 | 7.2 |
| 26 | F | 73.3 | 26 | + | + | 4 | + | − | − | − | + | 68 | 68 | 568.1 | 7.0 | 5.0 |
| 27 | F | 46.3 | 10 | − | − | 1.5 | − | − | − | − | + | 38 | 45 | NR | NR | NR |
| 28 | F | 58.5 | 0 | − | + | 3 | − | − | − | − | + | 50 | 54 | NR | NR | NR |
| 30 | F | 35.4 | 21 | − | − | 1.5 | − | − | − | + | + | 21 | 20 | NR | NR | NR |
| 32 | F | 45.9 | 34 (19 w/ med) | + | + | 2.5 | − | − | − | − | + | 38 | 17 | NR | NR | NR |
|
| ||||||||||||||||
| RLS − | ||||||||||||||||
|
| ||||||||||||||||
| 1 | F | 79.2 | − | − | − | 4 | + | − | − | − | + | 58 | − | 345.9 | 9.5 | 6.5 |
| 2 | F | 45.8 | − | − | − | 0 | − | − | − | + | − | n/a | − | 502.6 | 8.1 | 5.6 |
| 6 | F | 34.1 | − | + | − | 3 | − | − | − | − | + | 26 | − | 272.5 | 13.3 | 8.2 |
| 7 | M | 26.2 | − | − | − | 0 | − | − | − | − | − | n/a | − | 269.7 | 7.5 | 4.8 |
| 8 | M | 36.0 | − | + | − | 3.5 | + | + | + | − | + | 31 | − | 440.1 | 9.0 | 5.7 |
| 9 | F | 60.9 | − | − | − | 1.5 | − | − | − | + | + | NR | − | 487.7 | 6.8 | 5.2 |
| 11 | M | 20.7 | − | − | − | 1 | − | − | + | − | − | n/a | − | 518.2 | 5.0 | 4.4 |
| 12 | F | 49.4 | − | + | − | 1.5 | − | − | − | − | + | NR | − | 548.6 | 5.6 | 4.4 |
| 13 | M | 43.7 | − | − | − | 2.5 | − | + | + | − | + | 37 | − | 548.6 | 7.6 | 6.3 |
| 14 | M | 50.8 | − | − | − | 3.5 | − | + | + | − | + | 39 | − | 548.6 | 8.2 | 5.5 |
| 15 | F | 49.8 | − | + | − | 3 | − | − | − | + | + | 37 | − | 377.6 | 8.3 | 6.5 |
| 16 | M | 21.7 | − | − | + | 1.5 | − | − | + | − | − | n/a | − | 479.1 | 7.8 | 5.2 |
| 18 | M | 21.6 | − | − | − | 4 | − | + | + | − | + | 21 | − | 576.1 | 7.6 | 4.7 |
| 19 | F | 40.9 | − | − | − | 0 | − | − | − | − | − | n/a | − | NR | NR | NR |
| 20 | F | 49.5 | − | + | − | 3 | + | − | − | − | + | 30 | − | 330.4 | 14.9 | 10.5 |
| 21 | M | 40.0 | − | − | − | 3.5 | − | + | + | − | + | 31 | − | 460.6 | 9.1 | 5.6 |
| 23 | F | 64.8 | − | + | − | 6.5 | + | − | − | − | + | 35 | − | NR | NR | NR |
| 29 | F | 47.9 | − | + | − | 2 | − | − | − | − | + | 35 | − | NR | NR | NR |
| 31 | F | 57.4 | − | + | − | 6 | + | − | − | − | + | 42 | − | NR | NR | NR |
1
includes baclofen, gabapentin, and pramipexole
2
includes venlafaxine, escitalopram oxalate, bupropion, trazodone, citalopram, desvenlafaxine succinate
3
includes self-halted and stable brain lesions
AD = anti-depressant; AI = adrenal insufficiency, AMN = adrenomyeloneuropathy; ID = iron deficiency or anemia; NR = not recorded; TUG = timed up and go test; 25-FW = 25-foot walk test; 6MW = 6-minute walk test